Loading...
Header Logo
Keywords
Last Name
KP Region

Kai Yeung, PharmD, PhD

TitleAssistant Investigator
InstitutionKaiser Permanente Washington
DepartmentHealth Research Institute
ORCID ORCID Icon0000-0002-1102-2040 Additional info
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Kai Yeung, PharmD, PhD, is a pharmacist and scientist with expertise in pharmaceutical economics and outcomes research. He is interested in optimal incentives to encourage value in health care. Dr. Yeung does research in applied econometrics, health insurance design, and cost-effectiveness analysis. He received his PharmD from the University of Southern California and his PhD in pharmaceutical economics from the Pharmaceutical Outcomes Research & Policy Program at the University of Washington.

    Before joining KPWHRI in the fall of 2016, Dr. Yeung was a post-doctoral fellow at the University of Washington where he sought to understand payer acceptability of alternative payment models for high-priced curative therapies. He found that while payers were struggling with the affordability of high-priced cures, they were not aware of new payment models, but when educated by the research team, had high levels of acceptability to some of the new models.

    Dr. Yeung’s dissertation assessed the impact of a novel prescription drug benefit, the Value-Based Formulary (VBF) which used cost-effectiveness analysis to inform drug copayment tiers. He utilized econometric methods to quantify the impact of the VBF on beneficiary medication utilization behavior, health outcomes and health care expenditures from beneficiary and payer perspectives. For this work Dr. Yeung successfully competed for two research grants: a multidisciplinary research training grant from the National Center for Advancing Translational Sciences of the NIH and a health services research dissertation grant from the Agency for Healthcare Research and Quality. Different portions of this project have been recognized by the International Society for Pharmacoeconomics and Outcomes Research 2014 and 2015 annual meetings as the best student podium presentation award, and at the Vancouver Health Economics Methodology 2016 meeting as the best student paper award.

    During his PharmD training, Dr. Yeung has cultivated a broad perspective in the expanded use of evidence and analytics in decision-making, having worked with a diverse group of health care stakeholders, including:

    - patients (clinical pharmacy),
    - health care payers (Kaiser Permanente Drug Information Services),
    - federal agencies (AHRQ and FDA),
    - professional organizations (Academy for Managed Care Pharmacy), and
    - international technology assessment organizations (National Institute for Health and Clinical Excellence, UK).

    At KPWHRI, Dr. Yeung uses econometric methods to study questions related to drug benefits, specialty drug cost and outcomes, and designing value-based financial incentives.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Yeung K, Suh K, Basu A, Garrison LP, Bansal A, Carlson JJ. Paying for Cures: How Can We Afford It? Managed Care Pharmacy Stakeholder Perceptions of Policy Options to Address Affordability of Prescription Drugs. J Manag Care Spec Pharm. 2017 Oct; 23(10):1084-1090. PMID: 28944726.
      View in: PubMed
    2. Yeung K, Li M, Carlson JJ. Using Performance-Based Risk-Sharing Arrangements to Address Uncertainty in Indication-Based Pricing. J Manag Care Spec Pharm. 2017 Oct; 23(10):1010-1015. PMID: 28944729.
      View in: PubMed
    3. Yeung K, Basu A, Marcum ZA, Watkins JB, Sullivan SD. Impact of a value-based formulary in three chronic disease cohorts. Am J Manag Care. 2017 Mar; 23(3 Suppl):S46-S53. PMID: 29648740.
      View in: PubMed
    4. Yeung K, Basu A, Hansen RN, Watkins JB, Sullivan SD. Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures. Med Care. 2017 Feb; 55(2):191-198. PMID: 27579915.
      View in: PubMed
    5. Sullivan SD, Yeung K, Vogeler C, Ramsey SD, Wong E, Murphy CO, Danielson D, Veenstra DL, Garrison LP, Burke W, Watkins JB. Design, implementation, and first-year outcomes of a value-based drug formulary. J Manag Care Spec Pharm. 2015 Apr; 21(4):269-75. PMID: 25803760.
      View in: PubMed
    6. Carlson JJ, Gries KS, Yeung K, Sullivan SD, Garrison LP. Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers. Appl Health Econ Health Policy. 2014 Jun; 12(3):231-8. PMID: 24664994.
      View in: PubMed
    7. Gold LS, Yeung K, Smith N, Allen-Ramey FC, Nathan RA, Sullivan SD. Asthma control, cost and race: results from a national survey. J Asthma. 2013 Sep; 50(7):783-90. PMID: 23638955.
      View in: PubMed
    8. Vo AA, Petrozzino J, Yeung K, Sinha A, Kahwaji J, Peng A, Villicana R, Mackowiak J, Jordan SC. Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation. 2013 Mar 27; 95(6):852-8. PMID: 23511212.
      View in: PubMed
    Yeung's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    © 2019 Kaiser Permanente

    KP Researcher Profiles is funded by Kaiser Permanente Research.